Lilly Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and eight approved drugs.
There are two US patents protecting LILLY drugs.
There are forty-five patent family members on LILLY drugs in twenty-seven countries and eighty-eight supplementary protection certificates in thirteen countries.
Summary for Lilly
| International Patents: | 45 |
| US Patents: | 2 |
| Tradenames: | 87 |
| Ingredients: | 82 |
| NDAs: | 108 |
Drugs and US Patents for Lilly
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | NEBCIN | tobramycin sulfate | INJECTABLE;INJECTION | 050477-005 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Lilly | DICUMAROL | dicumarol | CAPSULE;ORAL | 005509-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Lilly | NEOTRIZINE | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | TABLET;ORAL | 006317-011 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-001 | Jul 10, 1986 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lilly
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,710,285 | See Plans and Pricing |
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-002 | Dec 29, 1989 | 4,452,745 | See Plans and Pricing |
| Lilly | PROZAC | fluoxetine hydrochloride | TABLET;ORAL | 020974-001 | Mar 9, 1999 | 4,626,549*PED | See Plans and Pricing |
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,843,984 | See Plans and Pricing |
| Lilly | ZYPREXA ZYDIS | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021086-002 | Apr 6, 2000 | 5,817,656 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
| ➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
| ➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
| ➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
| ➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
| ➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
| ➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
| ➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
International Patents for Lilly Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 200601801 | See Plans and Pricing |
| China | 100581607 | See Plans and Pricing |
| Japan | 2012180381 | See Plans and Pricing |
| South Korea | 100763051 | See Plans and Pricing |
| Brazil | PI0509269 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lilly Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1441735 | SPC/GB08/020 | United Kingdom | See Plans and Pricing | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| 0454436 | SPC/GB96/058 | United Kingdom | See Plans and Pricing | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 |
| 0720599 | 300689 | Netherlands | See Plans and Pricing | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 1718641 | 2012/008 | Ireland | See Plans and Pricing | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 1499331 | 13C0055 | France | See Plans and Pricing | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
